Annexon Submits Marketing Authorization Application for Tanruprubart to Treat Guillain-Barré Syndrome Louie Pasculli

Published Date: 14 Jan 2026

Annexon submitted an EMA marketing application for tanruprubart, a first-in-class C1q monoclonal antibody that showed faster and more complete recovery in Guillain-Barré syndrome patients across randomized trials.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Vaccine shows promise for pancreatic cancer, study finds

2.

After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.

3.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

Tumor characteristics found to differ for melanomas in children, teens and young adults


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot